Suppr超能文献

姜黄素与他林洛尔同时给药对健康中国志愿者他林洛尔药代动力学的意外影响。

Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers.

作者信息

Juan He, Terhaag Bernd, Cong Zang, Bi-Kui Zhang, Rong-Hua Zhu, Feng Wang, Fen-Li Su, Juan Song, Jing Tang, Wen-Xing Peng

机构信息

Clinical Pharmaceutical Research Institute, Second Xiangya Hospital, Central South University, Changsha 410011, People's Republic of China.

出版信息

Eur J Clin Pharmacol. 2007 Jul;63(7):663-8. doi: 10.1007/s00228-007-0298-0. Epub 2007 Apr 28.

Abstract

OBJECTIVE

To investigate the effect of concomitantly administered curcumin on the pharmacokinetics of the beta1 adrenoceptor blocker talinolol.

METHODS

The study was conducted in a self-controlled, two-period experiment with a randomized, open-labeled design, using 12 healthy volunteers and a wash out period of 1 week between the administration of a single oral dose of 50 mg talinolol and the concomitant administration of curcumin (300 mg day(-1) for 6 days) and a single oral dose of 50 mg talinolol on the seventh day. Concentrations of talinolol were measured in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Non-compartmental analysis was used to characterize talinolol plasma concentration-time profiles, all pharmacokinetic parameters were calculated using DAS: (ver. 2.0) software, and comparisons of mean values were analyzed by the Wilcoxon signed rank test. Differences were considered to be significant at p < 0.05 (two-sided test).

RESULTS

The consumption of curcumin for 6 days reduced the area under the curve (AUC) from predose to infinity (AUC(0-infinity)) of talinolol from 1860.0 +/- 377.9 to 1246.0 +/- 328.2 ng x h mL(-1), the highest observed concentration values (C(max)) were significantly decreased from 147.8 +/- 63.8 to 106.4 +/- 39.9 ng mL(-1), and the CL/F was increased from 27.9 +/- 5.5 to 43.1 +/- 13.4 L x h(-1) (p < 0.05). There was no significant difference in sampling time for C(max) (t(max)) and elimination half-life (t(1/2)) values between the two periods (p > 0.05). The interindividual variability in AUC(0-60) and C(max) of talinolol was comparable in two study periods; the coefficient of variance (CV) of AUC(0-60) and C(max) was 26 and 40% after curcumin versus 21 and 43% after talinolol alone, respectively.

CONCLUSION

We suggest that the reduced bioavailability of talinolol is most probably due to the low intraluminal curcumin concentration, or possibly due to the upregulation of further ATP-binding cassette transporters, such as MRP2, in different tissues.

摘要

目的

研究同时给予姜黄素对β1肾上腺素能受体阻滞剂他林洛尔药代动力学的影响。

方法

本研究采用自身对照、两阶段实验,随机开放标签设计,选取12名健康志愿者,在单次口服50 mg他林洛尔与同时给予姜黄素(300 mg·d⁻¹,共6天)之间设置1周的洗脱期,第7天再次单次口服50 mg他林洛尔。采用高效液相色谱-电喷雾电离质谱法测定血浆中他林洛尔的浓度。采用非房室分析法描述他林洛尔血浆浓度-时间曲线,使用DAS(版本2.0)软件计算所有药代动力学参数,采用Wilcoxon符号秩检验分析平均值的比较。p < 0.05(双侧检验)时差异被认为具有统计学意义。

结果

连续6天服用姜黄素使他林洛尔从给药前到无穷大的曲线下面积(AUC(0-∞))从1860.0 ± 377.9降至1246.0 ± 328.2 ng·h·mL⁻¹,最高观测浓度值(C(max))从147.8 ± 63.8显著降至106.4 ± 39.9 ng·mL⁻¹,清除率(CL/F)从27.9 ± 5.5增至43.1 ± 13.4 L·h⁻¹(p < 0.05)。两个阶段的C(max)达峰时间(t(max))和消除半衰期(t(1/2))值的采样时间无显著差异(p > 0.05)。两个研究阶段他林洛尔的AUC(0-60)和C(max)的个体间变异性相当;服用姜黄素后AUC(0-60)和C(max)的变异系数(CV)分别为26%和40%,单独服用他林洛尔后分别为21%和43%。

结论

我们认为他林洛尔生物利用度降低很可能是由于管腔内姜黄素浓度较低,或者可能是由于不同组织中其他ATP结合盒转运体(如MRP2)的上调。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验